Pharmaceutical company Galderma has released results from its phase III READY-3 clinical trial investigating the use of relabotulinumtoxinA for the treatment of glabellar lines and lateral canthal lines.
The study met its co-primary endpoints, with patients and investigators reporting at least a two-grade improvement in line severity after single-area treatment of frown lines (71%) or crow’s feet (45%) and simultaneous treatment (72% frown lines and 55% crow’s feet), compared to placebo at one month. The READY clinical trial programme is composed of four phase III trials which enrolled more than 1,900 participants, notes Galderma.
Investigator-reported response rates at one month were high, with 94-96% reporting none or mild frown lines when treated alone or simultaneously with crow’s feet, compared to placebo. Patient satisfaction was high, with up to 91% reporting satisfaction with simultaneous treatment at one month.
RelabotulinumtoxinA was also well-tolerated with low rates of treatment-related adverse events reported (4-9% compared to 5% for placebo). There were no serious treatment-related adverse events.
Baldo Scassellati Sforzolini, global head of research and development at Galderma, said, “These results build on those previously seen in the PHASE-1 and PHASE-2 trials, further reinforcing relabotulinumtoxinA’s ability to provide long-lasting improvement for frown lines and crow’s feet when treated simultaneously.”
